Last week, CHDI Foundation, a not-for-profit research organization, said it would "initially" pay up to 50 percent of clinical costs of a drug/device therapy being developed by Medtronic and Alnylam Pharmaceutical to treat Huntington's disease. While medical device and biopharmaceutical companies are partnering more and more, the inclusion of the foundation in this trio is what's interesting.
Medtronic Inc. (NYSE:MDT) said Wednesday it will form an alliance with a pharmaceutical firm and research foundation to develop a unique drug/device therapy to treat Huntington's disease. The medical firm, based in Fridley, Minnesota, said it will partner with Alnylam Pharmaceutical Inc. (Nasdaq:ALNY) and the CHDI Foundation to deliver a cutting-edge drug technology directly to the brain using an implantable infusion system being developed by Medtronic.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.